Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2016
Price : $35 *
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms LUPSENIC
- 05 Feb 2016 Status changed from recruiting to discontinued.
- 29 Aug 2013 Planned end date changed from 1 Jun 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 27 Dec 2012 New trial record